NVS / Novartis' (NVS) Sandoz Gets FDA Nod for Tysabri's Biosimilar

Novartis said its experimental drug atrasentan was shown to have a positive effect on kidney function in people suffering from a rare type of kidney d more_horizontal

Novartis recently completed the spin-off of Sandoz, which improved its growth and margin profile. The biopharma business is in good shape, with a dece more_horizontal

Novartis just spun off Sandoz, its generic division. The company has a huge pipeline of upcoming drug candidates. more_horizontal

Novartis AG (NYSE:NVS ) Q3 2023 Earnings Call Transcript October 24, 2023 8:00 AM ET Company Participants Samir Shah - Global Head of Investor Relatio more_horizontal

Novartis (NVS) beats on earnings in the third quarter and raises its annual guidance for core operating income. more_horizontal

Novartis CEO Vas Narasimhan discusses third-quarter results with the company lifting its profit forecast for a third time as he calls the drugmaker a more_horizontal

The Swiss pharmaceutical company says its transition to a pure-play innovative medicines business is now complete following the spinoff of Sandoz, its more_horizontal

Novartis on Tuesday raised its full-year earnings forecast for the third time on strong drug sales, after its generic drugs business Sandoz was spun o more_horizontal